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Simple Summary: Neuroendocrine neoplasms (NENs) of the gallbladder (GB) are extremely rare.
We aimed to compare the clinical features of GB-NENs with those of adenocarcinomas (ADCs) of
the GB. Among 21 patients with GB-NENs, 20 were diagnosed with poorly differentiated small-
cell neuroendocrine carcinoma (NEC), and 1 patient had large-cell NEC. At initial presentation,
all patients had advanced stages of cancer, with extensive local extension and/or distant metastasis.
Nine patients with GB-NEC who underwent surgical resection had a significantly better progression-
free survival (PFS) than those who did not undergo surgery. After a propensity score matching with
a 1:1 ratio using the American Joint Committee on Cancer (AJCC) stage, age, sex, and operation
status, there was no difference in the overall survival or PFS between AJCC stage-matched patients
with GB-NEC or GB-ADC. In conclusion, GB-NEC is difficult to diagnose early and has a prognosis
similar to that of GB-ADC.
Abstract: Neuroendocrine neoplasms (NENs) of the gallbladder (GB) are extremely rare. We aimed
to compare the clinical features, disease progression, management, and prognosis of patients with
GB-NENs with those of patients with GB-adenocarcinomas (ADCs). A total of 21 patients with
GB-NENs and 206 patients with GB-ADCs, treated at three tertiary medical centers between January
2010 and December 2020, were enrolled. Of the 21 patients with GB-NENs, 20 were diagnosed with
poorly differentiated small-cell neuroendocrine carcinomas (NECs), and 1 patient had large-cell NEC.
All patients presented with advanced stages of cancer with extensive local extension and/or distant
metastasis and non-specific symptoms. Tumor-node-metastasis stage IIIB and IV (A/B) tumors were
found in 6 and 15 (1/14) patients, respectively. Nine patients with GB-NEC who underwent surgical
resection had a significantly better progression-free survival (PFS) than those who did not undergo
surgery. After a propensity score matching with a 1:1 ratio using the American Joint Committee on
Cancer stage, age, sex, and operation status, 19 pairs of patients were included. Compared with
stage-matched patients with GB-ADC, patients with GB-NEC had similar overall survival and PFS.
However, as GB-NEC is rarely diagnosed early, further studies investigating methods for the early
diagnosis and improvement in the survival of patients with GB-NEC are needed.
Keywords: gallbladder; neuroendocrine neoplasm; neuroendocrine carcinoma; adenocarcinoma;
propensity score matching
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1. Introduction
Neuroendocrine neoplasms (NENs) are a rare malignant disease. According to the
National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database,
the incidence of NEN is 6.98 per 100,000 people [1,2]. NENs in the gastrointestinal tract are
the most common, found in 66% of all NENs. In the gastrointestinal tract, NENs commonly
occur in the rectum, ileum, stomach, colon, and pancreas, while gallbladder (GB) NENs are
extremely rare [3–5]. Previous studies have reported that primary GB-NENs were found in
only 0.5% of all NENs and comprised 2% of all GB cancers [6,7].
The first report on GB-NEN was published in 1929 [8]. Since then, small-cell and large-
cell carcinomas of the GB have been reported to have neuroendocrine differentiation [9].
According to the World Health Organization (WHO) classification published in 2019, NENs
are classified as neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and
mixed endocrine non-endocrine neoplasms (MiNENs) [10]. NENs are categorized based on
the degree of differentiation, proliferation, and molecular differences. Well-differentiated
NENs are categorized as neuroendocrine tumors (NETs), and poorly differentiated NENs
are categorized as neuroendocrine carcinomas (NECs) [10].
The pathogenesis and treatment of NENs are being determined rapidly; however, data
on GB-NENs are lacking. Unlike symptomatic NENs of the gastrointestinal tract, GB-NENs
are asymptomatic and usually found at an aggressive stage [11]. There is no consensus
on the treatment strategy for GB-NEN due to its low incidence and unknown course of
disease. Currently, the treatment of GB-NEN is similar to that of adenocarcinoma (ADC) of
the GB, which is the most common GB cancer. Despite the lack of an established surgical
strategy, radical surgical resection is often considered [12–14].
We aimed to retrospectively analyze the clinical features, disease progression, manage-
ment, and prognosis of GB-NENs. In addition, we compared survival outcomes in patients
with GB-NENs with those with GB-ADCs using a propensity score-matched cohort.
2. Materials and Methods
2.1. Patients
Patients with GB-NENs who were treated at three tertiary medical centers (Gangnam
Severance Hospital, Gil Medical Center, and National Cancer Center) between January
2010 and December 2020 were included in the study. Data related to these patients were
retrospectively collected from electronic medical records.
The inclusion criteria were as follows: (1) the primary tumor site was GB; (2) patients
were diagnosed with GB-NENs based on pathology and immunohistochemistry, according
to the 2019 WHO classification [10]; and (3) the medical records and data of the patients
were accurate and detailed. The exclusion criteria were as follows: (1) MiNENs with an
ADC component of ≥30%; (2) patients without detailed and intact the medical records
or data. patients with GB-ADCs were selected for propensity score matching with pa-
tients with GB-NENs. Between January 2010 and 21 December 2020 cases of GB-NENs
(all patients had G3 NECs) and 206 cases of GB-ADC were included in the study.
2.2. Pathological Classification and Staging
The diagnosis of GB-NENs was based on the 2019 WHO classification of tumors
of the digestive system. GB-NENs are classified into well-differentiated NETs, poorly
differentiated NEC, and MiNENs. GB-NENs are classified as grades 1, 2, and 3 (G1, G2,
and G3) based on their mitotic rate and/or the Ki-67 index: G1, mitotic rate of <2 per
2 mm2 and/or Ki-67 index of <3%; G2, mitotic rate of 2 to 20 per 2 mm2 and/or Ki-67 index
of 3 to 20%; and G3, mitotic rate of >20 per 2 mm2 and/or Ki-67 index of >20%. GB-NECs
are classified as small-cell type or large-cell type. MiNENs consist of a neuroendocrine
component or non-neuroendocrine component, such as an adenocarcinoma [10].
The tumor-node-metastasis (TNM) stage of GB neoplasms was determined according
to the 8th American Joint Committee on Cancer (AJCC) staging system (Table S1) [15].
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2.3. Statistical Analysis
Differences between the two groups were compared using the independent two-
sample test for continuous variables or the chi-square test for categorical variables. The
Kaplan–Meier method was used to evaluate the overall survival outcomes in the two
groups. Propensity score values for the predicted probability of survival in patients with
GB-NENs and GB-ADCs were estimated using logistic regression analysis, with age, sex,
stage, and operation status as confounding variables. Participants with GB-NENs were
matched to those with GB-ADC in a 1:1 manner using a nearest-neighbor matching method
with a greedy algorithm. All p-values were two-sided. Statistical significance was set
at p < 0.05. Statistical analyses were performed using SPSS software (version 25.0; IBM
Corporation, Armonk, NY, USA).
3. Results
3.1. Clinical Features of GB-NENs
Of the 21 patients, 11 (52.4%) were male (Table 1). The median patient age was 62.0
(range, 31–84) years. The initial clinical presentations were abdominal pain (n = 18, 85.8%),
jaundice (n = 6, 28.6%), weight loss (n = 4, 19%), and pruritus (n = 1, 4.8%). Serum levels of
tumor biomarkers were measured. CA19-9 was elevated in 7 out of the 21 patients, with
a median value of 22.6 U/mL (normal value < 37 U/mL), and carcinoembryonic antigen
was elevated in 2 out of the 21 patients with values of 1265.3 and 5.6 ng/mL (normal
value <5.0 ng/mL). All 21 patients underwent computed tomography (CT), which showed
space-occupying lesions in the GB. The findings were similar to those observed in patients
with GB-ADCs (Figure 1).
Table 1. Clinical features of 21 cases of gallbladder neuroendocrine carcinoma.
Variables Median (Range) or n (%)




Clinical symptom, n (%)
Abdominal discomfort 18 (85.8)
Jaundice 6 (28.6)
Weight loss 4 (19.0)
Pruritus 1 (4.8)
Tumor marker, median (range)
CA19-9 (U/mL) 22.6 (0.6–696.7)
CEA (ng/mL) 2.2 (0.5–1265.3)
NEN classification, n (%)
NEC, small-cell type 20 (95.2)
NEC, large-cell type 1 (4.8)
Differentiated degree, n (%)
Grade 1/2 0/0
Grade 3 21 (100)
Ki-67 index, n (%)
>20 17 (81.0)
Unknown 4 (19.0)
Immunohistochemical stain, n (%)
CgA 17 (81.0)
Syn 18 (85.7)
NSE (test in 1 case) 1 (100)
CD56 (test in 15 cases) 11 (73.3)
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Table 1. Cont.
Variables Median (Range) or n (%)









Lt. subclavian lymph node 1
Operation, n (%) 9 (42.9)
Curative 7
Palliative 2
Chemotherapy, n (%) 15 (71.4)
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CgA, chromogranin A; NEC, neuroendocrine carcinoma; NEN,
neuroendocrine neoplasm; NSE, neuron-specific enolase; Syn, synaptophysin; TNM, tumor node metastasis.
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was elevated in 17 patients (>20%). Immunohistochemical staining was used to evaluate 
NEC biomarkers. Chromogranin A and synaptophysin were positive in 17 (81.0%) and 18 
Figure 1. Computed tomography images of gallbladder neuroendocrine carcinoma and adenocarcinoma. (A) Gallbladder
neuroendocrine carcinoma with direct invasion and metastases to the liver and regional lymph nodes. (B) Gallbladder
adenocarcinoma with direct invasion and metastases to the liver and regional lymph nodes.
3.2. Histopathological Features and Staging
According to the 2019 WHO classification, all patients with GB-NENs were diagnosed
with poorly differentiated grade 3 (G3) GB-NECs; 20 patients were diagnosed with small-
cell NEC, and 1 patient was diagnosed with large-cell NEC. The Ki-67 index was elevated in
17 patients (>20%). Immunohistochemical staining was used to evaluate NEC biomarkers.
Chromogranin A and synaptophysin were positive in 17 (81.0%) and 18 (85.7%) patients,
respectively. Positive rates for neuro-specific enolase and CD56 were 100% (tested in
1 patient) and 73.3% (tested in 15 patients), respectively.
At the time of initial diagnosis, all patients presented with advanced cancer with
extensive local extension and/or distant metastasis. The number of patients with TNM
stages IIIB, IVA, and IVB was 6, 1, and 14, respectively. The liver was the most common
site of metastasis in 10 patients (47.6%). Metastases to the bone, peritoneum, ovary, and left
subclavian lymph nodes were observed in one (4.8%) case each.
3.3. Treatments and Clinical Outcomes
Surgical treatments were performed in 9 of the 21 (42.9%) patients with GB-NEC.
Three patients underwent radical cholecystectomy, four patients underwent extended
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cholecystectomy with hepatic resection, and two patients underwent a simple cholecystec-
tomy for palliative therapy. Postoperative chemotherapy was administered to seven of the
nine patients. Among the remaining 12 patients, 8 patients received only chemotherapy,
and four patients were not treated. A summary of clinical characteristics of the patients
with GB-NEC is shown in Table S2.
The median survival was 460 days (range, 15–928 days), and the median progression-
free survival (PFS) was 137 days (range, 15–577 days). The median overall survival of
operated and non-operated patients was 416.0 days (range, 72–928 days) and 85.5 days
(range, 15–348 days), respectively. There was no significant difference between the groups
(log rank test p = 0.134). The median PFS of operated and non-operated patients was
211.0 days (range, 72–577 days) and 61.5 days (range, 15–156 days), respectively, and
the difference was statistically significant (log-rank test, p = 0.036) (Figure 2). Univariate
survival analysis demonstrated that age and sex had no prognostic significance.
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3.4. Propensity Score Analysis
The clinical features, treatments and outcomes of 206 patients with GB-ADC are shown
in Table S3. Before propensity score matching, the median overall survival of patients
with GB-NECs and GB-ADCs was 166 days (range, 15–928 days) and 309 days (range,
19–6552 days). There were no significant differences in overall survival (log rank test
p = 0.153) (Figure S1). The median PFS of patients with GB-NECs and GB-ADCs was
81 days (range, 15–577 days) and 277 days (range, 19–6552 days), and the difference was
statistically significant (log-rank test, p < 0.001) (Figure S2). Since the stage was different
between patients with GB-NEC and ADC, we conducted propensity score matching.
Propensity score matching for the predicted probability of survival in patients with
GB-NECs and GB-ADCs was performed using age, sex, stage, and operation status as
confounding variables. After propensity score matching with a 1:1 ratio, 19 pairs of patients
were included in this study. In addition, density plot of propensity score is shown in Figure S3.
The baseline characteristics of the pre- and post-matched groups are presented in
Table 2. There were no significant differences between the two matched groups with
respect to age, sex, TNM stage, and operation. The median overall survival and median
PFS of patients with GB-NECs and GB-ADCs was 460 days (range, 15–928 days) and
545 days (range, 35–2396 days), and 156 days (range, 15–577 days) and 300 days (range,
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35–2396 days), respectively. There were no significant differences in the overall survival nor
PFS between patients with GB-NECs and those with GB-ADCs after matching the AJCC
stages (log rank test p = 0.752, p = 0.373, respectively) (Figures 3 and 4).
Table 2. Clinical characteristics of gallbladder neuroendocrine carcinoma and gallbladder adenocarcinoma (before and after
propensity score matching).













Age, years, mean (SD) 64.2 ± 14.3 65.0 ± 11.1 0.059 0.774 64.6 ± 15.1 63.1 ± 13.8 −0.102 0.755
Sex, n (%) 0.471 0.746
Male 11 (52.4) 91(44.2) −0.165 9 (47.4) 10 (52.6) 0.105
Female 10 (47.6) 115 (55.8) 0.165 10 (52.6) 9 (47.4) −0.105
TNM stage, n (%) 0.011 >0.999
I 0 (0.0) 17 (8.3) 0.424 0 (0.0) 0 (0.0) 0.000
II 0 (0.0) 32 (15.5) 0.606 0 (0.0) 0 (0.0) 0.000
IIIa 0 (0.0) 10 (4.9) 0.319 0 (0.0) 0 (0.0) 0.000
IIIb 6 (28.6) 15 (7.3) −0.578 4 (21.1) 4 (21.1) 0.000
IVa 1 (4.8) 6 (2.9) −0.096 1 (5.3) 2 (10.5) 0.196
IVb 14 (66.7) 126 (61.2) −0.115 14 (73.7) 13 (68.4) −0.116
Operation, n (%) 9 (42.9) 115 (55.8) 0.262 0.255 7 (36.8) 9 (47.4) 0.214 0.511
Chemotherapy, n (%) 15 (71.4) 141 (68.4) −0.065 0.779 13 (68.4) 14 (73.7) 0.116 0.721
ADC, adenocarcinoma; GB, gallbladder; NEC, neuroendocrine carcinoma; PS, propensity score; TNM, tumor node metastasis. Data are
presented as mean (SD) or number (%). p-values are calculated by independent two sample t-test for continuous variables or Chi-squared
test for categorical variables.
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4. Discussion
GB-NENs are very rarely encountered in clinical practice [6,16,17]. Therefore, the liter-
ature regarding these tumors is largely limited to case reports with literature reviews and
a few small-case seri s. Thus, th assessment of the clinical characteristics and prognosis
of patients with GB-NENs is limited. We investigated the clinical features and outcomes
of 21 patients with GB-NENs who underwent treatment at three tertiary medical centers
between 2010 and 2020. In most previous reports, GB-NENs were confirmed as GB-NECs,
and, in this study, all 21 cases were identified as GB-NECs. Therefore, we used propensity
score matching for an objective and accurate comparison of the characteristics of GB-NECs
with those of GB-ADCs.
GB-NEC is highly malignant with aggressive progression, and systemic metasta-
sis is common, even in the early stages. Most patients are diagnosed at an aggressive
stage [17–19]. The clinical presentation of GB-NEC is non-specific compared with that
of GB-ADC. As most of these cases are non-functional NECs, the presence of carcinoid
syndrome is rare [20–22]. With the advancements in imaging techniques, imaging exami-
nations including CT, magnetic resonance imaging, and positron emission tomography-CT
are helpful for diagnosis of GB diseases. A well-defined margin is the most significant CT
finding in GB-NECs compared to GB-ADCs. GB-NECs are mass-replacing tumors with a
well-defined margin, while GB-ADCs are thick-walled tumors with poorly defined margins
due to their infiltrative nature [23–25].
The definite diagnosis of GB-NEC requires pathology and immunohistochemistry.
Currently, the most commonly used specific biomarkers are chromogranin A (CgA), synap-
tophysin (Syn), and neuro-specific enolase [26]. In a previous study involving 15 patients
with GB-NECs, CgA and Syn had positive rates of 92.3% and 100%, respectively [11]. In
another study, there were eight patients with GB-NEC. CgA and Syn were positive in all
cases [27]. In addition, CgA is a soluble secretory glycoprotein secreted by dense-core secre-
tory of neuroendocrine cells [28–30], and it has been found that 60% to 80% of NENs in the
digestive system contain elevated serum CgA levels [31–33]. Serum CgA is related to tumor
burden, and the serial measurement of CgA may be useful to detect recurrence [29,34].
In a previous study involving 44 patients with NENs, the sensitivity and specificity of
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CgA for detecting NEN were 86% and 88%, respectively [31]. In our study, more than 80%
of cases showed positive staining for CgA and synaptophysin in immunohistochemical
staining. However, during the study period, the introduction and application of serum
chromogranin under the Korean National Health Insurance Service was difficult, so the
test could not be performed.
According to the statistics of the SEER database, the pathological degree of differ-
entiation of GB-NEC has been reported as well-differentiated tumors (2.4%), moderately
differentiated tumors (7.3%), and poorly or undifferentiated tumors (89.7%) [6]. In addition,
previous studies have reported that an elevated Ki-67 index and a high mitotic rate are
likely to be predictive of a poor prognosis [35,36]. More than 90% of small-cell carcinomas
are poorly differentiated, with regional or distant metastasis at diagnosis [37]. In our study,
all 21 patients with GB-NECs showed poorly differentiated tumors, with Ki-67 index >20,
and small-cell type NECs, which were seen in 20 patients, were predominant.
In general, the only curative therapeutic modality for GB cancer is surgical resection.
Moreover, because extensive debulking resection is preferred for gastroenteropancreatic
NENs, surgical resection is one of the most important treatments for GB-NECs. Although
a surgical treatment strategy for GB-NECs has not been established, previous studies
have recommended aggressive radical cholecystectomy, including lymph node dissection
and/or hepatic resection. A previous study showed that patients who underwent surgery
had better survival than those who did not [12–14]. In the SEER database, patients with
GB-NENs who underwent GB surgery had better survival than patients who did not [1].
Radical resection has a significantly better survival outcome than non-operative palliative
treatment [12]. In contrast, the outcome after palliative resection is not significantly different
from that after non-operative palliative treatment [12]. In a previous study involving
15 patients with GB-NECs, radical cholecystectomy was performed in 10 patients. The
overall survival after surgical treatment was not significantly longer than that after non-
surgical treatment [11]. In the present study, nine patients underwent surgical treatment,
including radical cholecystectomy and simple cholecystectomy, and all patients classified
as TNM stage III underwent radical cholecystectomy. Similar to the results of previous
studies, patients with GB-NEC who underwent surgery had a significantly better PFS than
those who underwent non-surgical treatment.
The prognosis of patients with GB-NECs is reported to be relatively worse com-
pared with that of patients with GB-ADCs. In a retrospective analysis of 10 patients with
GB-NECs, the median survival was 3.0 months, and the one-, two-, and three-year cu-
mulative survival rates were 20%, 10%, and 0%, respectively. In contrast, the median
survival in 377 patients with GB-ADCs treated during the same period was 6.0 months,
and the one-, two-, three-, and 5-year survival rates were 38.0%, 31.0%, 30.1%, and 28.4%,
respectively [17]. In a study of 15 propensity-matched pairs of patients with GB-NECs
and ADCs, patients with GB-NECs had a worse overall survival rate than those with
GB-ADCs [11]. However, this small retrospective study included five patients with MiNEC
among 15 patients with GB-NECs. Yun et al. [13] compared the overall five-year survival
rate between four patients with GB-NECs and 38 patients with GB-ADCs and reported no
significant differences between the two groups. Interestingly, these results were similar
to our findings that there was no difference in prognosis between GB-NEC and GB-ADC
among patients matched according to their AJCC stage, which is the strongest prognostic
factor [19]. In the preliminary comparison between the GB-NEC and GB-ADC cohorts, it
was confirmed that GB-NEC is difficult to diagnose early, and most cases are diagnosed at
an advanced stage. The reasons for this are as follows: GB-ADC is diagnosed at various
stages because, in some patients, it is incidentally diagnosed early, following laparoscopic
cholecystectomy for the removal of gallstones or polyps [9,38]. However, as GB-NEC is
highly malignant and progresses aggressively, most patients are diagnosed at a late stage,
when the opportunity for surgical treatment has been lost. Moreover, early diagnosis is
difficult due to the lack of research into the pathophysiology of GB-NEC. Several studies
have suggested that adjuvant chemotherapy is needed at an advanced stage of GB-NEC,
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even if radical resection is completed. Adjuvant chemotherapy is the treatment of choice
when radical resection is not feasible [27,39–41]. In our study, 15 out of the 21 patients
received chemotherapy; however, the chemotherapy regimen was inconsistent.
There are several limitations to our study. First, this was a retrospective study, and
there were only 21 patients with GB-NEC. Due to the insufficient number of patients,
we could not validate statistical comparisons by multivariate analysis. However, we
conducted statistical comparisons using propensity score matching and compared the
outcomes of patients with GB-NEC with those of patients with GB-ADC. Second, to
compare the typical characteristics of GB-NEC, MiNENs were excluded from the analysis.
However, because many GB-NECs were diagnosed as MiNENs, their characteristics could
not be confirmed in this study. Third, accurate values of serum CgA and exact percentage of
the Ki-67 index were not confirmed due to the limitations of the retrospective study. Lastly,
the heterogeneity of treatments including various chemotherapeutic agents and surgery
might have influenced the therapeutic outcomes and prognosis of patients with GB-NEC.
Our propensity matching analysis indicated that patients with GB-NEC had prog-
noses similar to those with GB-ADC in the matched AJCC stage. In addition, GB-NEN
is asymptomatic, and usually found in an advanced stage of GB-NEC. The univariate
analysis showed that surgery helped progression-free survival: patients who underwent
surgery showed better progression-free survival than those who did not. Further stud-
ies investigating the early diagnosis and improvement in the survival of GB-NEC are
needed [42].
Due to the lack of research on the mechanism of occurrence and treatment, further lab-
oratory and clinical studies with large sample sizes are needed to establish early diagnosis
and improvement in the survival of those with GB-NENs.
5. Conclusions
GB-NECs are poorly differentiated tumors that have non-specific symptoms, and
they are diagnosed at an advanced clinical stage. Pathological and immunohistochemical
evaluations are required to confirm the diagnosis. Aggressive radical cholecystectomy
is the preferred treatment option. Although uncertain, chemotherapy is critical for the
management of unresectable GB-NEC. The AJCC stage-based propensity-score-matched
analysis showed that patients with GB-ADC had an overall survival and PFS similar to pa-
tients with GB-NEC. Further studies investigating the early diagnosis and improvement in
the survival of patients with GB-NEC are needed.
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